|
|
|
|
|
|
|
25.08.25 - 14:09
|
XFRA: 2SX: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
SCPHARMACEUTIC. DL -,0001 2SX US8106481059
AB/FROM ONWARDS 25.08.2025 14:03 CET...
|
|
|
25.08.25 - 14:06
|
XFRA: 2SX: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
SCPHARMACEUTIC. DL -,0001 2SX US8106481059 BAW/UFN...
|
|
|
|
|
|
|
|
|
14.08.25 - 14:33
|
scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111 (GlobeNewswire EN)
|
|
|
BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, announced today that it has received five Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering their latest furosemide formulation, SCP-111. The SCP-111 formulation is the subject of a supplemental NDA expected to be filed by the Company this quarter. The five patents, once issued, will join four additional patents owned by the Company that cover the SCP-111 formulation....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
